Explore the words cloud of the POLYMMUNE project. It provides you a very rough idea of what is the project "POLYMMUNE" about.
The following table provides information about the project.
FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE
|Coordinator Country||Spain [ES]|
|Total cost||149˙938 €|
|EC max contribution||149˙938 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2019-01-01 to 2020-06-30|
Take a look of project's partnership.
|1||FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE||ES (VALENCIA)||coordinator||149˙938.00|
Despite various existing drug delivery methods, the key challenge remains: how to deliver drugs to the desired site of therapeutic action to achieve best treatment outcome, while minimising side effects? This is even more challenging in cancer immunotherapy as a complex interplay of immune reactions need to be activated. POLYMMUNE will evaluate the technical and commercial viability of our novel polymeric nanocarrier platform (developed during my ERC Consolidator grant MyNano) for targeted drug delivery of a wide variety of diseases and therapeutics. As proof of concept, we will focus on immunotherapy delivery for metastatic melanoma. Globally ~132,000 new melanoma cases will be diagnosed each year and despite recent successes, only 50% of the patients respond to novel immunotherapies that are costly, while causing severe side effects. Coupling a commercially available antigen against metastatic melanoma to our nanocarrier will activate a broad immune response, resulting in an effective cancer vaccine that potentially targets different melanoma types, enabling off-the-shelf production. This dual action will lead to increased clinical benefit, which will come with less side effects and will be 5-10-fold cheaper than current treatments. Additionally, our conjugate is industrially scalable and thus overcome a major bottle neck of current nanocarrier-based medicine. We envision our platform technology to be used as a method of choice for drug delivery in many medical applications, such as cancer immunotherapy and neurodegenerative diseases. These applications are within reach, as depending on the modification, our conjugates can e.g. bypass the blood brain barrier and potentially be administered intranasally (nanogel). Our platform offers a highly attractive business case, as biotechnology and pharmaceutical companies heavily invest in nanoconjugates due to the need for novel drug delivery strategies.
|year||authors and title||journal||last update|
Liane I. F. Moura, Alessio Malfanti, Carina Peres, Ana I. Matos, Elise Guegain, Vanessa Sainz, Mire Zloh, MarÃa J. Vicent, Helena F. Florindo
Functionalized branched polymers: promising immunomodulatory tools for the treatment of cancer and immune disorders
published pages: , ISSN: 2051-6347, DOI: 10.1039/c9mh00628a
|Materials Horizons Advanced article||2019-08-29|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYMMUNE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "POLYMMUNE" are provided by the European Opendata Portal: CORDIS opendata.